Oscar rises after upbeat guidance offsets underwhelming Q4 results
Oscar Health rose in premarket trading after reporting impressive full-year guidance that more than offset Q4 results that failed to live up to analysts’ expectations.
For the last three months of 2025, Oscar reported:
A loss per share of $1.24, compared to the $0.89 loss per share analysts polled by FactSet were expecting.
Revenue of $2.8 billion, lower than the $3.1 billion Wall Street was penciling in.
A medical cost ratio of 95.4%, higher than the 91.1% analysts expected.
For the full year in 2026, Oscar expects:
Revenues between $18.7 billion and $19 billion, compared to the $12.4 billion analysts had penciled in.
Its medical cost ratio to sit between 82.4% and 83.4%, while analysts had expected 85.5%.
Health insurers have been under pressure for the past year amid rising health costs. Oscar, a provider of ACA Marketplace plans, has taken a hit as tax credits for the program lapsed in January.